Conference programme

Virtual Meeting (Eastern Africa Time)


Download the full programme

Download the list of abstracts

Tuesday, 2 November 2021

Opening Session


ModeratorDr Sultani Matendechero, Chairperson of the LEAP Advisory Committee (LAC), Ministry of Health, Kenya
Welcome and IntroductionDr Monique Wasunna, DNDi, Kenya
 Prof Muntaser Ibrahim, University of Khartoum, Sudan
Prof. Samuel Kariuki
, Kenya Medical Research Institute, Kenya
Rolland Kaya
, Médecins Sans Frontières Eastern Africa, Kenya
Juliet Nabyonga-Orem, World Health Organization, Kenya
Dr Bernard Pécoul
, DNDi, Switzerland
Keynote SpeakerDr Margaret Anyetei-Agama, African Union, Ethiopia

Session 1 – Leishmaniasis Prevention, Epidemiology, Vector Control and Elimination


Dr Alfred Mubangizi, Ministry of Health, Uganda
Dr Mousab S. Elhag, Federal Ministry of Health, Sudan
13:45-14:00Towards Elimination of Visceral Leishmaniasis in Eastern Africa
Dr Daniel Argaw, World Health Organization, Switzerland
14:00-14:15Unmet needs in the knowledge of Vector Control in Eastern Africa
Prof. Dia El Naiem, University of Maryland, USA
14:15-14:30Structuring the political agenda for Leishmaniasis in Eastern Africa
Dr Abate Mulugeta, Regional Office for Africa – World Health Organization, Republic of Congo
14:30-14:45Prospects of visceral leishmaniasis elimination in Eastern Africa: applicable lessons drawn from Southeast Asia elimination initiative
Dr Saurabh Jain
, WHO-TDR, Switzerland
14:45-15:00A concerted endeavour for elimination of kala-azar in Eastern Africa for 2030
Dr Carol Karutu, The END Fund, Kenya
15:00-15:15The Global Vector Hub – building entomological capacity worldwide and improving epidemic preparedness
Dr Frederik Seelig, London School of Hygiene & Tropical Medicine, United Kingdom
15:15-15:30Discussion / Q&A
15:30-16:00Poster Presentations

Wednesday, 3 November 2021

Session 2 – Advances in R&D and access, diagnosis, and Treatment for Leishmaniasis


Dr Jane Mbui, Kenya Medical Research Institute (KEMRI), Kenya
Dr Yaw Asare Aboagye, DNDi, Kenya
12:40-12:55Phase III PM/MF clinical trial – a more user-friendly option for children with VL
Alexandra Solomos, DNDi, Switzerland
12:55-13:10Opportunities in diagnostics and test of cure for VL in Eastern Africa
Dr Henk Schallig, Academic Medical Centre, The Netherlands
13:10-13:20Investigation of the interactions of some anti-leishmanial natural compounds with potential protein targets: an in-silico approach
Abigail Adomako, Kwame Nkrumah University of Science and Technology, Ghana
13:20-13:30Capparis spinosa inhibits Leishmania major promastigote and amastigote growth through induction of Nitric Oxide production
Dounia DARIF, Hassan II University of Casablanca, Morocco
13:30-13:40Financial & Administrative Challenges in Clinical Trials Implementation in Resource Limited Settings: Experiences from DNDi sponsored clinical trials in eastern Africa
Simon Bolo, DNDi, Kenya
13:40-13:55Progress made on the VL Data Platform, and plans
Dr Prabin Dahal, Infectious Diseases Data Observatory (IDDO), University of Oxford, UK

Session 3 – Current Advances in Cutaneous Leishmaniasis


Prof. Asrat Hailu, Addis Ababa University, Ethiopia
Dr Esther Kinyeru, Gilgil Hospital, Kenya
14:25-14:40CL in Africa
Prof. Mourad Mokni, University Tunis Al Manar, Tunisia
14:40-14:55Epidemiological situation of CL in Ethiopia
Endalamaw Gadisa, Armauer Hansen Research Institute, Ethiopia
14:55–15:10CL: Asian perspective and effects on quality of Life
Prof. Nadira Karunaweera, University of Colombo, Sri Lanka
15:10–15:25DNDi Efforts on CL
Dr Byron Arana, DNDi, Switzerland
15:35-16:05Poster Presentations

Thursday, 4 November 2021

Session 4 – Leishmaniasis: Basic Science, Translational Research and Vaccine Development


Prof. Eltahir Khalil Gasim, Institute of Endemic Diseases, University of Khartoum, Sudan
Prof. Paul Kaye, University of York, UK
12:40-12:55Immunological determinants of chronic visceral leishmaniasis in HIV-coinfected patients
Nicky de Vrij, Institute of Tropical Medicine Antwerp, Belgium
12:55-13:20Immunology of L. infantum and L. major infections
Dr Thourya Boussoffara, Institut Pasteur, Tunisia
13:20-13:35Immunology of PKDL and CL in South East Asia
Prof. Mitali Chatterjee, Post Graduate Institute of Medical Education & Research (PGIMER), India
13:35-13:50Development of a centrin-based vaccine for VL
Dr Angamuthu Selvapandiyan, Jamia Hamdard University, India

Session 5 – Special Session on the Impact of COVID-19 on NTDs and Training on Fundraising Tools in Africa


Prof. Yalemtsehay Mekonnen, Addis Ababa University, Ethiopia
Dr Irene Mukui, DNDi, Kenya
14:10-15:10Training: Key tools to raise funds for projects and organizations in Africa
Karin Genevaux, Genoka Services, France
15:20-15:35Effects of COVID-19 on visceral leishmaniasis activities in Uganda
Prof. Joseph Olobo, Makerere University, Uganda
Q&A: Open discussion on COVID-19 in Africa: Where are we,
Lessons Learnt and What More Needs to be Done
15:35- 15:55COVID-19 in Africa: Where are we, Lessons Learnt and What More Needs to be Done
Dr Mohammed Abdulaziz, Africa CDC, Ethiopia
15:55-16:15Q&A: Open discussion on COVID-19 in Africa

Session 6: Closing Session


Worldleish7 UpdateProf. Ivan D. Velez, Universidad de Antiqioquia, Colombia
Wrap up and Close of ConferenceDr Jorge Alvar, DNDi, Switzerland